File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Management of hepatocellular carcinoma in renal transplant recipients

TitleManagement of hepatocellular carcinoma in renal transplant recipients
Authors
KeywordsHepatectomy
Hepatocellular carcinoma
Renal transplantation
TOCE
Issue Date2004
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/31873
Citation
Journal Of Surgical Oncology, 2004, v. 87 n. 3, p. 139-142 How to Cite?
AbstractBackground and Objective: In Hong Kong where hepatitis B virus (HBV) infection is endemic, hepatocellular carcinoma (HCC) accounts for 20% of all malignant transformations in renal transplant recipients. The aim of the present study was to review the management and outcome of HCC in renal transplant recipients at a specialized surgical center. Method: A retrospective analysis on the data collected prospectively in a tertiary referral center. Results: From January 1991 to December 2002, five renal transplant recipients were diagnosed to have primary HCC and received treatment in our center. There were four men and one woman with a median age of 47 (range, 38-68) years. Four of them had cadaveric renal transplantation whereas one had live donor transplantation. All of them were HBV carriers. The median tumor size was 3.5 cm (range, 1.8-8 cm). All tumors, except one, were diagnosed in sub-clinical stage by surveillance serum α-fetoprotein assay and percutaneous ultrasonography. Four patients were treated with surgical resection and one received transarterial oily chemoembolization (TOCE) as their primary treatments. There was one peri-operative death and the remaining three surgically treated patients were alive 4, 62, and 64 months after the resection. One patient developed recurrence 18 months after curative resection and was treated with TOCE. The patient with unresectable disease was alive for 50 months after the initial diagnosis. The surgical resection and overall survival rates of these patients were better than the published results. Conclusion: Early detection with regular serum α-fetoprotein assay and ultrasonographic study, vigilant care in the peri-operative period, long-term follow-up for detection and treatment of recurrence, as well as close collaboration between renal physicians and liver surgeons may improve the outcome of treatment of HCC in renal transplant recipients. © 2004 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/84181
ISSN
2015 Impact Factor: 3.151
2015 SCImago Journal Rankings: 1.349
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChok, KSHen_HK
dc.contributor.authorLam, CMen_HK
dc.contributor.authorLi, FKen_HK
dc.contributor.authorNg, KKen_HK
dc.contributor.authorPoon, RTen_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-06T08:49:55Z-
dc.date.available2010-09-06T08:49:55Z-
dc.date.issued2004en_HK
dc.identifier.citationJournal Of Surgical Oncology, 2004, v. 87 n. 3, p. 139-142en_HK
dc.identifier.issn0022-4790en_HK
dc.identifier.urihttp://hdl.handle.net/10722/84181-
dc.description.abstractBackground and Objective: In Hong Kong where hepatitis B virus (HBV) infection is endemic, hepatocellular carcinoma (HCC) accounts for 20% of all malignant transformations in renal transplant recipients. The aim of the present study was to review the management and outcome of HCC in renal transplant recipients at a specialized surgical center. Method: A retrospective analysis on the data collected prospectively in a tertiary referral center. Results: From January 1991 to December 2002, five renal transplant recipients were diagnosed to have primary HCC and received treatment in our center. There were four men and one woman with a median age of 47 (range, 38-68) years. Four of them had cadaveric renal transplantation whereas one had live donor transplantation. All of them were HBV carriers. The median tumor size was 3.5 cm (range, 1.8-8 cm). All tumors, except one, were diagnosed in sub-clinical stage by surveillance serum α-fetoprotein assay and percutaneous ultrasonography. Four patients were treated with surgical resection and one received transarterial oily chemoembolization (TOCE) as their primary treatments. There was one peri-operative death and the remaining three surgically treated patients were alive 4, 62, and 64 months after the resection. One patient developed recurrence 18 months after curative resection and was treated with TOCE. The patient with unresectable disease was alive for 50 months after the initial diagnosis. The surgical resection and overall survival rates of these patients were better than the published results. Conclusion: Early detection with regular serum α-fetoprotein assay and ultrasonographic study, vigilant care in the peri-operative period, long-term follow-up for detection and treatment of recurrence, as well as close collaboration between renal physicians and liver surgeons may improve the outcome of treatment of HCC in renal transplant recipients. © 2004 Wiley-Liss, Inc.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/31873en_HK
dc.relation.ispartofJournal of Surgical Oncologyen_HK
dc.rightsJournal of Surgical Oncology. Copyright © John Wiley & Sons, Inc.en_HK
dc.subjectHepatectomyen_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectRenal transplantationen_HK
dc.subjectTOCEen_HK
dc.titleManagement of hepatocellular carcinoma in renal transplant recipientsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0022-4790&volume=87&issue=3&spage=139&epage=142&date=2004&atitle=Management+of+hepatocellular+carcinoma+in+renal+transplant+recipientsen_HK
dc.identifier.emailPoon, RT: poontp@hkucc.hku.hken_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityPoon, RT=rp00446en_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/jso.20098en_HK
dc.identifier.pmid15334642-
dc.identifier.scopuseid_2-s2.0-4444253523en_HK
dc.identifier.hkuros96810en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-4444253523&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume87en_HK
dc.identifier.issue3en_HK
dc.identifier.spage139en_HK
dc.identifier.epage142en_HK
dc.identifier.isiWOS:000223673300007-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChok, KS=6508229426en_HK
dc.identifier.scopusauthoridLam, CM=7402989820en_HK
dc.identifier.scopusauthoridLi, FK=8219093900en_HK
dc.identifier.scopusauthoridNg, KK=7403179075en_HK
dc.identifier.scopusauthoridPoon, RT=7103097223en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats